Sygnature Discovery
Kerry Waters
Business Development DirectorRachel Hemsley
Business Development Director
The Science Behind
The Science Behind specialise in integrating cutting-edge non-invasive neurostimulation and neuroimaging technologies and services to enhance Phase I clinical trials.
Innovatively applying techniques such as transcranial magnetic stimulation (TMS), quantitative sensory testing (QST) and electroencephalography (EEG), either independently or in combination with cognitive or physiological assessments, The Science Behind excels in addressing crucial questions related to target engagement, dose response and the timing of efficacy.
Our approach provides information on how a drug impacts various aspects of central nervous system function. This deeper insight into the neural mechanisms of drug action in humans serves to guide the development of new treatments, potentially enhancing their prospects for success in future clinical trials.

Vernalis
Vernalis collaborates with a wide range of organisations to enable drug discovery programs through both short- and long-term projects. By applying our deep and wide expertise in structure-based drug discovery, built over twenty-five years of partnerships and innovation to enable challenging targets, we can express and engineer your proteins, find and validate hits and help to evolve your chemical series into pre-clinical candidates. And we can do all this in-house at our fully equipped laboratories in Cambridge UK.